Allergan is a healthcare company. It focuses on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products. The company markets a portfolio of brands and products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system, and gastroenterology.

Employee Rating

3.9More
TypeSubsidiary
Parent CompanyAbbVie
HQDublin, IE
Founded1948
Websiteallergan.com
Cybersecurity ratingBMore
Allergan was founded in 1948 and is headquartered in Dublin, IE

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Allergan

Edward M. Liddy

Edward M. Liddy

Director
Jeffrey R. Stewart

Jeffrey R. Stewart

Executive Vice President, Chief Commercial Officer
Rae L. Livingston

Rae L. Livingston

Chief Equity Officer
Tara Capalbo

Tara Capalbo

Vice President of Marketing, Neurosciences & Urology
Erin Newton

Erin Newton

Vice President, Sales
Fraser Halscheid

Fraser Halscheid

Vice President International Strategic Marketing
Show more

Allergan Office Locations

Allergan has offices in Dublin, Westport, Austin, Irvine and in 37 other locations
Dublin, IE (HQ)
Clonshaugh Business & Technology Park
Dublin, IE
Longphort House, Block J, The Earlsfort Centre Lower Leeson Street
Westport, IE
Castlebar Rd
Buenos Aires, AR
Av. del Libertador 498 Piso 29
Gordon, AU
Level 4/810 Pacific Hwy
Wien, AT
Twin Tower, Wienerbergstraße 11/12A
Show all (43)

Allergan Financials and Metrics

Summary Metrics

Founding Date

1948
Allergan is a subsidiary of AbbVie

Allergan Revenue

Embed Graph
View revenue for all periods
Allergan's revenue was reported to be $16.09 b in FY, 2019 which is a 1.9% increase from the previous period.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

15.9b15.8b16.1b

Revenue growth, %

9%(1%)2%

Cost of goods sold

2.2b2.2b2.5b

Gross profit

13.8b13.6b13.6b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

3.7b4.1b3.9b3.6b4.1b4.1b3.6b

Cost of goods sold

522.8m481.8m596.8m497.8m652.3m639.0m623.1m

Gross profit

3.1b3.6b3.3b3.1b3.4b3.4b3.0b

Gross profit Margin, %

86%88%85%86%84%84%83%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

1.8b880.4m2.5b

Accounts Receivable

2.9b2.9b3.2b

Inventories

904.5m846.9m1.1b

Current Assets

11.4b6.5b11.1b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

994.8m1.7b1.2b788.5m1.7b1.2b999.5m

Accounts Receivable

2.6b2.8b2.8b2.7b3.1b3.0b2.8b

Inventories

948.4m922.5m894.6m943.2m1.0b1.1b1.2b

Current Assets

6.4b6.1b5.7b6.3b8.6b9.6b7.5b
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(4.1b)(5.1b)(5.3b)

Depreciation and Amortization

7.4b6.7b6.1b

Inventories

(144.8m)(145.7m)(393.4m)

Accounts Payable

95.9m151.6m1.4b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(283.9m)(754.0m)(790.3m)(2.4b)(4.2b)(4.9b)379.0m

Depreciation and Amortization

1.8b3.5b5.1b1.4b2.9b4.5b1.5b

Inventories

(52.7m)(113.3m)(136.2m)(128.3m)(179.3m)(328.9m)(126.3m)

Accounts Payable

(231.6m)(40.4m)(46.1m)(199.8m)161.6m874.9m(1.2b)
USDFY, 2017

Revenue/Employee

895.5k

Debt/Equity

0.4 x

Debt/Assets

0.3 x

Financial Leverage

1.6 x
Show all financial metrics

Allergan Operating Metrics

FY, 2016Q1, 2017Q2, 2017Q3, 2017FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020

Countries

100100100100100100100100100100100100100100

Key Promoted Products

36251718

Facilities

17212121

Facilities Leased

7111111
Show all operating metrics

Allergan Acquisitions / Subsidiaries

Company NameDateDeal Size
BontiSeptember 14, 2018$195 m
ElastagenFebruary 07, 2018$95 m
Repros TherapeuticsDecember 12, 2017
ZELTIQ Aesthetics (CoolSculpting)February 15, 2017$2.48 b
Lysosomal TherapeuticsJanuary 09, 2017
LifeCellDecember 20, 2016$2.9 b
Chase PharmaceuticalsNovember 22, 2016$125 m
Motus TherapeuticsOctober 27, 2016$200 m
Akarna TherapeuticsSeptember 20, 2016
Tobira TherapeuticsSeptember 20, 2016$1.7 b
Show more

Allergan Revenue Breakdown

Embed Graph

Allergan revenue breakdown by business segment: 21.1% from International, 36.3% from US General Medicine, 42.4% from US Specialized Therapeutics and 0.2% from Other

Show all human capital metrics

Allergan Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Allergan Online and Social Media Presence

Embed Graph

Allergan Company Culture

  • Overall Culture

    C-

    63/100

  • CEO Rating

    B

    72/100

  • Compensation

    C-

    60/100

  • Diversity

    C+

    67/100

Learn more on Comparably

Allergan News and Updates

Worldwide Neuralgia Treatment Industry to 2027 - Players Include Allergan, GlaxoSmithKline & Biogen Among Others

Dublin, March 19, 2021 (GLOBE NEWSWIRE) -- The "Neuralgia Treatment Market Size, Share & Trends Analysis Report, By Treatment; By End-Use; By Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global neuralgia treatment market size is pred…

Worldwide Dermal Facial Fillers Industry to 2026 - Featuring Allergan, Galderma & Merz Pharma Among Others

Dublin, March 01, 2021 (GLOBE NEWSWIRE) -- The "Dermal Facial Fillers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global dermal facial fillers market reached a value of US$ 2.64 Billion in …

Outlook on the Cephalosporin Global Market to 2026 - Players Include Allergan, GlaxoSmithKline and Lupin Among Others

Dublin, Feb. 23, 2021 (GLOBE NEWSWIRE) -- The "Cephalosporin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global cephalosporin market reached a value of US$ 17.46 Billion in 2020. Cephalospo…

Global Anterior Uveitis Treatment Market (2020 to 2026) - Featuring Mylan, Allergan & Cadila Pharmaceuticals Among Others

Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Global Anterior uveitis treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global anterior uveitis treatment market is projected to witness considerable growth during the forecast period. The major factors cont…

Worldwide Contraceptive Devices Industry to 2025 - Players Include Allergan Plc, Bayer Healthcare and Cooper Surgical Among Others

Dublin, Feb. 04, 2021 (GLOBE NEWSWIRE) -- The "Contraceptive Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The global contraceptive devices market grew at a CAGR of around 7% during 2014-…

CoolSculpting by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting Elite

European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis.read more
Show more

Allergan Blogs

Allergan Shareholders Approve Proposed Acquisition by AbbVie

DUBLIN, Oct. 14, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONS...

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

- Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year - - Abicipar sustained vi...

Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction

 DUBLIN, Sept. 27, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE REL...

AbbVie Inc. - Despatch of Option Holder Proposal Letters

NORTH CHICAGO, Ill., Sept. 20, 2019 /PRNewswire/ -- In accordance with Rule 15(c) of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. ("AbbVie") and Allergan plc ("Allergan") announce that letters dated 20 September 2019 containing details of the proposal (the "Proposal") to hold…

Announcement under the Irish Takeover Rules: Relevant Securities in Issue - September 17, 2019

DUBLIN, Sept. 17, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...

Allergan Shareholder Meetings Scheduled for October 14, 2019

DUBLIN, Sept. 10, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATIO...
Show more

Allergan Frequently Asked Questions

  • When was Allergan founded?

    Allergan was founded in 1948.

  • Who are Allergan key executives?

    Allergan's key executives are Edward M. Liddy, Jeffrey R. Stewart and Rae L. Livingston.

  • How many employees does Allergan have?

    Allergan has 17,400 employees.

  • What is Allergan revenue?

    Latest Allergan annual revenue is $16.1 b.

  • What is Allergan revenue per employee?

    Latest Allergan revenue per employee is $924.6 k.

  • Who are Allergan competitors?

    Competitors of Allergan include Alcon, Genentech and Amgen.

  • Where is Allergan headquarters?

    Allergan headquarters is located at Clonshaugh Business & Technology Park, Dublin.

  • Where are Allergan offices?

    Allergan has offices in Dublin, Westport, Austin, Irvine and in 37 other locations.

  • How many offices does Allergan have?

    Allergan has 43 offices.